24 de octubre de 2019
  • Miércoles, 23 de Octubre
  • 31 de agosto de 2009

    In Heart Failure Patients Treated With ACE Inhibitor and/or Beta Blocker, Higher Plasma Renin Activity is Related to Gre

    The foregoing release contains forward-looking statements that can be identified by terminology such as "potential," "predicts," "can," or similar expressions, or by express or implied discussions regarding potential new indications or labelling for Rasilez/Tekturna or regarding potential future revenues from Rasilez/Tekturna. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Rasilez/Tekturna to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Rasilez/Tekturna will be approved for any additional indications or labelling in any market. Nor can there be any guarantee that Rasilez/Tekturna will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Rasilez/Tekturna could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    About Novartis

    Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

    References

    1 Masson S et al. Plasma renin activity retains a strong prognostic value in patients with chronic HF, independent of ACE inhibitor or beta-blocker therapy. Data from the Valsartan Heart Failure Trial (Val-HeFT). Presented at the European Society of Cardiology (ESC) Congress 2009.

    2 Vergaro G, Fontana M, Poletti R, et al. Plasma renin activity is an independent prognostic factor in chronic heart failure. Eur Heart J 2008;29(Suppl):393(Abstract 2493).

    3 Bair TL, May HT, Prescott MF, et al. Association between baseline levels of plasma renin activity and risk of cardiovascular events. Presented at the American College of Cardiology scientific sessions, 29-31 March 2009, Orlando, FL, USA.

    4 Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:221-228.

    5 Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-256.

    6 Taylor AA, Anderson DR, Arora V, et al. Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: a pooled analysis of 1093 patients with hypertension. J Am Coll Cardiol 2007;49(9 Suppl. A):370A P-1014-1170.

    7 Parsi A. Anaemia in heart failure: its diagnosis and management. The European Journal of Heart Failure 2003;5:3-4.

    8 Cohn JN et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001;345(23):1667-1675.

    9 Maggioni, AP et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology 2002;40(8 ):1414-1421.

    Novartis Media Relations: Central media line: +41-61-324-2200. Eric Althoff, Novartis Global Media Relations, +41-61-324-7999 (direct), +41-79-593-4202 (mobile), eric.althoff@novartis.com. Yanyan Chang, Novartis Pharma Communications, +41-61-324-2339 (direct), +41-79-292-0959 (mobile), yanyan.chang@novartis.com, e-mail: media.relations@novartis.com. Novartis Investor Relations: Central phone: +41-61-324-7944; Ruth Metzler-Arnold, +41-61-324-9980; Pierre-Michel Bringer, +41-61-324-1065; John Gilardi, +41-61-324-3018; Thomas Hungerbuehler, +41-61-324-8425; Isabella Zinck, +41-61-324-7188; e-mail: investor.relations@novartis.com. North America: Richard Jarvis, +1-212-830-2433; Jill Pozarek, +1-212-830-2445; Edwin Valeriano, +1-212-830-2456